The Global Drug sales of Lynparza stood at USD 2,638 Millions in 2022
The indicator recorded a historical growth (CAGR) of30% between 2019 to 2022 and is expected to grow by ...
GlobalData projects the indicator to grow at a CAGR of...
Olaparib (Lynparza) is an antineoplastic agent. It is formulated as hard gelatin capsules, coated tablets and film-coated tablets for oral route of administration.
Mechanism of Action
Olaparib acts as an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. It selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks. PARP inhibition enhances the cytotoxicity of DNA-damaging agents and reverses the tumor cell chemoresistance and radioresistance. Olaparib-induced cytotoxicity involves inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.
Lynparza Overview
Lynparza is indicated for the treatment of the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and somatic) high grade serous epithelial ovarian, liposarcoma, bone arcoma, soft tissue sarcoma, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy. Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy, and also indicated for the first line maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy, as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations (gBRCAm), and who have human epidermal growth factor receptor 2 (HER2)-negative locally-advanced or metastatic breast cancer, as a first line maintenance treatment for women with BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of 1st-line platinum-based chemotherapy. Lynparza is also indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) whose disease has not progressed on at least 16 weeks of a 1st-line platinum-based chemotherapy regimen, and also in combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Lynparza for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.
Keytruda was first approved in 2014 and is sold globally including the US, the UK, France, Germany, and Japan by several pharma giants including Merck & Co Inc, and AstraZeneca Plc. Keytruda drug sales recorded a mid-double digit Year on Year growth in 2022. Keytruda drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer